Skip to main content
SpringerLink
Log in
Book cover

Micrometastasis pp 173–183Cite as

Minimal Residual Disease in Melanoma

  • Chapter

  • 230 Accesses

Part of the Cancer Metastasis - Biology and Treatment book series (CMBT,volume 5)

Abstract

A number of specific genes encoding for melanosomal proteins are selectively expressed in melanocytes and melanomas. For detection of circulating melanoma cells, the expression of the tyrosinase gene is most widely used. Several cohorts of melanoma patients from single institutions have been analyzed by various research groups for the presence of circulating melanoma cells in all stages of disease. The percentage of patients with evidence for occult tumor dissemination has been correlated with the stage of disease in several, but not all, reports. Two prospective analyses suggest that the PCR result is of prognostic value in melanoma. Several laboratories have found PCR evidence for circulating melanoma cells in the great majority of untreated patients with Stage IV disease, other groups have reported much lower frequencies. Taken together, there is a wide range of results. Methodological differences are likely to account for this discrepancy. With the availability of true quantitative real-time reverse transcriptase (RT)-PCR systems, accurate quantification of tyrosinase transcripts over a range of 1 to 10,000 tumor cells per milliliter of blood is possible. Quantitative real-time RT-PCR systems also dramatically improve quality control, since exact quantitation of housekeeping gene mRNA facilitates determination of sample quality. Two large clinical trials are currently under way within the EORTC and in the US to adequately determine the clinical usefulness of PCR detection of minimal residual disease in melanoma.

Keywords

  • Melanoma Cell
  • Clin Oncol
  • Melanoma Patient
  • Circulate Tumor Cell
  • Minimal Residual Disease

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Caron M, Jorgensen G, Rigel D, Friedman R. In: Blach CM, Houghton AN, Miltron GM, editors. The Worldwide Incidence of Malignant Melanoma. Philadelphia: JB Lippincott, 1992, pp. 27–45.

    Google Scholar 

  2. Lakhani S, Selby P, Bliss JM, Perren TJ, Gore ME, McElwain TJ. Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit. Brit J Cancer. 1990; 61: 330–334.

    CrossRef  PubMed  CAS  Google Scholar 

  3. Buzaid AC and Balch CM. Polymerase chain reaction of melanoma in peripheral blood: too early to assess clinical value. J Natl Cancer Inst. 1996; 88: 569–570.

    CrossRef  PubMed  CAS  Google Scholar 

  4. Cross NC, Feng L, Chase A et al. Competitive polymerase chain reaction to estimate the number of bcr-abl transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood. 1993; 82: 1929–1936.

    PubMed  CAS  Google Scholar 

  5. Fukuhara T, Hooper WC, Baylin SB et al. Use of the polymerase chain reaction to detect hypermethylation in the calcitonin gene — a new, sensitive approach to monitor tumor cells in acute myelogenous leukemia. Leukemia Res. 1992; 16: 1031–1040.

    CrossRef  CAS  Google Scholar 

  6. Curry BJ, Smith MJ, Hersey P. Detection and quantitation of melanoma cells in the circulation of patients. Melanoma Res. 1996; 6: 45–54.

    CrossRef  PubMed  CAS  Google Scholar 

  7. Brossart P, Keilholz U, Willhauck M, Scheibenbogen C et al. Hematogenous spread of malignant melanoma cells in different stages of disease. J Invest Dermatol. 1993; 101: 887–889.

    CrossRef  PubMed  CAS  Google Scholar 

  8. Brossart P, Schmier J-W, Krüger S et al. A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. Cancer Res. 1995; 55: 4056–4068.

    Google Scholar 

  9. Brossart P, Keilholz U, Scheibenbogen C et al. Detection of residual tumor cells in patients with malignant melanoma responding to immunotherapy. J Immunotherapy. 1994; 15: 38–41.

    CrossRef  CAS  Google Scholar 

  10. Adema G de Boer AJ van’t Hullenaar R et al. Melacyte lineage-specific antigens recognized by moclonal antibodies NKI-beteb HMB-50 and HMB-45 are encoded by a single cDNA. Am J Path. 1993; 143 1579–1585.

    PubMed  CAS  Google Scholar 

  11. Adema GJ, de Boer AJ, Vogel AM et al. Molecular characterization of the melanoma lineage-specific antigen gp100. J Biol Chem. 1994; 269: 20126–20133.

    PubMed  CAS  Google Scholar 

  12. Kawakami Y, Eliyahu S, Delgado CH et al. Cloning the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA. 1994; 91: 3515–3519.

    CrossRef  PubMed  CAS  ADS  Google Scholar 

  13. Carrel S, Dore JF, Ruiter D et al. The EORTC melanoma group exchange program: evaluation of a multicenter monoclonal antibody study. Int J Cancer. 1991; 48: 836–847.

    CrossRef  PubMed  CAS  Google Scholar 

  14. Scheibenbogen C, Weyers I, Ruiter D, Willhauck M, Bittinger A, Keilholz U. Expression of gp100 in melanoma metastases resected before or after treatment with IFN alpha and IL-2. J Immunother 1996; 19: 375–380.

    CrossRef  CAS  Google Scholar 

  15. Chen YT, Stockert E, Tsang S et al. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci USA. 1995; 92: 8125–8129.

    CrossRef  PubMed  CAS  ADS  Google Scholar 

  16. Marincola FM, HiJazi YM, Fetsch P et al. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in situ lesions. J Immunotherapy. 1996; 19: 192–205.

    CrossRef  CAS  Google Scholar 

  17. Coulie PG, Brichard V, van Pel A et al. A new gene coding for a differentiation antigen recognized by autologous cytoloytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1994; 180: 35–42.

    CrossRef  PubMed  CAS  Google Scholar 

  18. Gaugler B, Van den Eynde B, van der Bruggen P et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytoloytic T lymphocytes. J Exp Med. 1994; 179: 921–930.

    CrossRef  PubMed  CAS  Google Scholar 

  19. Brasseur F, Rimoldi D, Lienard D et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer. 1995; 63: 375–380.

    CrossRef  PubMed  CAS  Google Scholar 

  20. De Plaen E, Arden K, Traversari C et al. Structure, chromosomal localization and expression of twelve genes of the MAGE family. Immunogenetics. 1994; 40: 360–369.

    CrossRef  PubMed  CAS  Google Scholar 

  21. Smith B, Selby P, Southgate J et al. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet. 1991; 338: 1227–1229.

    CrossRef  PubMed  CAS  Google Scholar 

  22. Tobal K, Sherman LS, Foss AJ, Lightman SL. Detection of melanocytes from uveal melanoma in peripheral blood using the polymerase chain reaction. Invest Ophthalmol Vis Sci. 1993; 34: 2622–2625.

    PubMed  CAS  Google Scholar 

  23. Battyani Z, Grob J, Xerri L et al. PCR detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch Dermatol. 1995; 131: 443–447.

    CrossRef  Google Scholar 

  24. Hoon DS, Wang Y, Dale PS et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol. 1995; 13: 2109–2116.

    PubMed  CAS  Google Scholar 

  25. Foss AJ, Guille MJ, Occleston NL et al. The detection of melanoma cells in peripheral blood by reverse transcription polymerase chain reaction. Brit J Cancer. 1995; 72: 155–159.

    CrossRef  PubMed  CAS  Google Scholar 

  26. Kunter U, Buer J, Probst M et al. Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst. 1996; 88: 590–594.

    CrossRef  PubMed  CAS  Google Scholar 

  27. Tsao H, Nadiminti U, Sober AJ, Bigby M. A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma. Arch Dermatol. 2001; 137: 325–330.

    PubMed  CAS  Google Scholar 

  28. Mellado B, Colomer D, Castel T et al. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. J Clin Oncol. 1996; 14: 2091–2097.

    PubMed  CAS  Google Scholar 

  29. de Vries TJ, Fourkour A, Punt CJ, van de Locht LT et al. Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR. Brit J Cancer. 1999; 80: 883–891.

    CrossRef  PubMed  Google Scholar 

  30. Chen YT, Stockert E, Tsang S et al. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci USA. 1995; 92: 8125–8129.

    CrossRef  PubMed  CAS  ADS  Google Scholar 

  31. Scheibenbogen C, Weyers I, Ruiter D et al. Expression of gp100 in melanoma metastases resected before or after treatment with IFN alpha and IL-2. J Immunother Emphasis Tumor Immunol. 1996; 19: 375–380.

    PubMed  CAS  Google Scholar 

  32. Wang X, Heller R, VanVoorhis N, Cruse CW et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg. 1994; 220: 768–774.

    CrossRef  PubMed  CAS  Google Scholar 

  33. Max N, Wolf K, Spike B et al. Nested quantitative real-time PCR for detection of occult tumor cells. Recent Results Cancer Res. 2001; 158: 25–31.

    PubMed  CAS  Google Scholar 

  34. Keilholz U, Willhauck M, Rimoldi D, Brasseur F, Dummer W, Rass K, de Vries T, Blaheta J, Voit C, Lrthe B, Burchill L. Reliability of reverse transcription-polymerase chain reaction (RT-PCR)-based assays for the detection of circulating tumor cells: a quality-assurance initiative of the EORTC melanoma cooperative group. EJC. 1998; 34: 750–753.

    CrossRef  CAS  Google Scholar 

  35. Stevens GL, Scheer WD, Levine EA. Detection of tyrosinase mRNA from the blood of melanoma patients. Cancer Epidemiol Biomarkers Prev. 1996; 5: 293–296.

    PubMed  CAS  Google Scholar 

  36. Glaser R, Rass K, Seiter S et al. Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: a clinical two-center study. J Clin Oncol. 1997; 15: 2818–2825.

    PubMed  CAS  Google Scholar 

  37. Reinhold U, Ludtke-Handjery HC, Schnautz S et al. The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. J Invest Dermatol. 1997; 108: 166–169.

    CrossRef  PubMed  CAS  Google Scholar 

  38. Jung FA, Buzaid AC, Ross MI et al. Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J Clin Oncol. 1997; 15: 2826–2831.

    PubMed  CAS  Google Scholar 

  39. Tessier MH, Denis MG, Lustenberger P, Dreno B. Detection of circulating neoplastic cells by reverse transcriptase and polymerase chain reaction in melanoma. Ann Dermatol Verel. 1997; 124: 607–611.

    CAS  Google Scholar 

  40. Farthmann B, Eberle J, Krasagakis K et al. RT-PCR for tyrosinase-mRNA positive cells in peripheral blood: evaluation strategy and correlation with known prognostic markers in 123 melanoma patients. J Invest Dermatol. 1998; 110: 263–267.

    CrossRef  PubMed  CAS  Google Scholar 

  41. Ghossein RA, Coit D, Brennan M et al. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. Clin Cancer Res. 1998; 4: 419–428.

    PubMed  CAS  Google Scholar 

  42. O’Connell CD, Juhasz A, Kuo C et al. Detection of tyrosinase mRNA in melanoma by reverse transcription PCR and electrochemiluminescence. Clin Chem. 1998; 44: 1161–1169.

    Google Scholar 

  43. Voit C, Schoengen A, Schwurzer M et al. Detection of regional melanoma metastases by ultrasound B-scan, cytology or tyrosinase RT-PCR of fine-needle aspirates. Brit J Cancer. 1999; 80: 1672–1677.

    CrossRef  PubMed  CAS  Google Scholar 

  44. Palmieri G, Strazzullo M, Ascierto PA et al. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group. J Clin Oncol. 1999; 17: 304–311.

    PubMed  CAS  Google Scholar 

  45. Mellado B, Gutierrez L, Castel T et al. Prognostic siginificance of the detection of circulating malignant cells by reverse transcriptase polymerase chain reaction in long-term clinically disease-free melanoma patients. Clin Cancer Res. 1999; 5: 1843–1848.

    PubMed  CAS  Google Scholar 

  46. Le Bricon T, Stoitchkov K, Letellier S et al. Simultaneous analysis of tyrosinase mRNA and markers of tyrosinase activity in the blood of patients with metastatic melanoma. Clin Chim Acta. 1999; 282: 101–113.

    CrossRef  PubMed  Google Scholar 

  47. Schittek B, Bodingbauer Y, Ellwanger U et al. Amplification of MelanA messenger RNA in addition to tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of malignant melanoma. Brit J Dermatol. 1999; 141: 30–36.

    CrossRef  CAS  Google Scholar 

  48. Curry BJ, Myers K, Hersey P. MART-1 is expressed less frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases. J Clin Oncol. 1999; 17: 2562–2571.

    PubMed  CAS  Google Scholar 

  49. Hanekom GS, Stubbings HM, Johnson CA, Kidson SH. The detection of circulating melanoma cells correlates with tumor thickness and ulceration but is not predictive of metastasis for patients with primary melanoma. Melanoma Res. 1999; 9: 465–473.

    CrossRef  PubMed  CAS  Google Scholar 

  50. Alao JP, Mohammed MQ, Slade MJ, Retsas S. Detection of tyrosinase mRNA by RT-PCR in the peripheral blood of patients with advanced metastatic melanoma. Melanoma Res. 1999; 9: 395–399.

    CrossRef  PubMed  CAS  Google Scholar 

  51. Kopreski MS, Benko FA, Kwak LW, Gocke CD. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin Cancer Res. 1999; 5: 1961–1965.

    PubMed  CAS  Google Scholar 

  52. de Vries TJ, Fourkour A, Punt CJ, van de Locht LT, Wobbes T, van den Bosch S, de Rooij MJ, Mensink EJ, Ruiter DJ, van Muijen GN. Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR. Br J Cancer 1999; 80: 883–91.

    CrossRef  PubMed  Google Scholar 

  53. Proebstle TM, Jiang W, Hogel J, Keilholz U, Weber L, Voit C. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors. Brit J Cancer. 2000; 82: 118–123.

    CrossRef  PubMed  CAS  Google Scholar 

  54. Brownbridge GG, Gold J, Edward M, MacKie RM. Evaluation of the use of tyrosina-sespecific and melanA/MART-1-specific reverse transcriptase-coupled-polymerase chain reaction to detect melanoma cells in peripheral blood samples from 299 patients with malignant melanoma. Br J Dermatol. 2001; 144: 279–287.

    CrossRef  PubMed  CAS  Google Scholar 

  55. Reinhold U, Berkin C, Bosserhoff AK, Deutschmann A et al. Interlaboratory evaluation of a new reverse transcriptase polymerase chain reaction-based enzymelinked immunosorbent assay for the detection of circulating melanoma cells: a multicenter study of the Dermatologic Cooperative Oncology Group. J Clin Oncol. 2001; 19: 1723–1727.

    PubMed  CAS  Google Scholar 

  56. Stoitchkov K, Letellier S, Garnier JP, Toneva M, Naumova E, Peytcheva E, Tzankov N, Bousquet B, Morel P, Le Bricon T. Evaluation of standard tyrosinase RT-PCR in melanoma patients by the use of the Light Cycler system. Clin Chim Acta. 2001; 306: 133–138.

    CrossRef  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine III, University Hospital Benjamin Franklin, Free University Berlin, Hindenburgdamm 30, 12200, Berlin, Germany

    Petra Goldin-Lang & Ulrich Keilholz

Authors
  1. Petra Goldin-Lang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrich Keilholz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institute of Tumour Biology, University Hospital Hamburg-Eppendorf, Germany

    Klaus Pantel (Director) (Director)

Rights and permissions

Reprints and Permissions

Copyright information

© 2003 Kluwer Academic Publishers

About this chapter

Cite this chapter

Goldin-Lang, P., Keilholz, U. (2003). Minimal Residual Disease in Melanoma. In: Pantel, K. (eds) Micrometastasis. Cancer Metastasis - Biology and Treatment, vol 5. Springer, Dordrecht. https://doi.org/10.1007/0-306-48355-6_9

Download citation

  • DOI: https://doi.org/10.1007/0-306-48355-6_9

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-1-4020-1155-9

  • Online ISBN: 978-0-306-48355-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

search

Navigation